natgillin/translations-raw huggingface dataset:
Ebymect 5 mg/850 mg film-coated tablets Ebymect 5 mg/1,000 mg film-coated tablets 
Ebymect 5 mg/850 mg filmsko obložene tablete Ebymect 5 mg/1000 mg filmsko obložene tablete
Reported in ≥ 2 % of subjects and ≥ 1 % more and at least 3 more subjects treated with dapagliflozin 10 mg compared to placebo. 
Glejte poglavje 4.4 Opisano pri ≥ 2 % preiskovancev ter pri ≥ 1 % več in pri vsaj 3 preiskovancih več med uporabo 10 mg dapagliflozina kot med uporabo placeba.
Uncommon Rare 
Neraziskane kombinacije
Each Ebymect 5 mg/1,000 mg film-coated tablet (tablet) contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin and 1,000 mg metformin hydrochloride. 
Ena filmsko obložena tableta (tableta) zdravila Ebymect 5 mg/1000 mg vsebuje dapagliflozinpropandiol monohidrat v količini, ki ustreza 5 mg dapagliflozina, in 1.000 mg metforminijevega klorida.
How to store Ebymect 
Shranjevanje zdravila Ebymect
Ebymect 5 mg/850 mg film-coated tablets Ebymect 5 mg/1,000 mg film-coated tablets dapagliflozin/metformin hydrochloride 
Ebymect 5 mg/850 mg filmsko obložene tablete Ebymect 5 mg/1000 mg filmsko obložene tablete dapagliflozin/metforminijev klorid
Liver function disorders Hepatitis 
Bolezni jeter, žolčnika in žolčevodov motnje delovanja jeter
Ebymect 5 mg/850 mg tablets dapagliflozin/metformin HCl 
Ebymect 5 mg/850 mg tablete dapagliflozin/metforminijev klorid
Ebymect 5 mg/1,000 mg tablets dapagliflozin/metformin HCl 
Ebymect 5 mg/1000 mg tablete dapagliflozin/metforminijev klorid
• a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034; 
• značilno zmanjšanje absolutnega tveganja vseh zapletov sladkorne bolezni v skupini z metforminom (29,8 dogodka/1000 bolnik-let) v primerjavi z dieto samo (43,3 dogodka/1000
Ebymect 5 mg/1,000 mg film-coated tablets dapagliflozin/metformin hydrochloride 
Ebymect 5 mg/1000 mg filmsko obložene tablete dapagliflozin/metforminijev klorid
Mean percent change from baseline for dapagliflozin 10 mg versus placebo, respectively, was: total cholesterol 2.5 % versus 0.0 %; HDL cholesterol 6.0 % versus 2.7 %; LDL cholesterol 2.9 % versus -1.0 %; triglycerides -2.7 % versus -0.7 %. 
Povprečni odstotek spremembe od izhodišča za 10 mg dapagliflozina v primerjavi s placebom je bil: celotni holesterol 2,5 % v prim.
Ebymect 5 mg/850 mg film-coated tablets dapagliflozin/metformin hydrochloride 
Ebymect 5 mg/850 mg filmsko obložene tablete dapagliflozin/metforminijev klorid
• by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis; 
Metformin lahko deluje po treh mehanizmih: • z zmanjšanjem nastajanja glukoze v jetrih z zavrtjem glukoneogeneze in glikogenolize,
suicidal thoughts or suicide attempts. 
samomorilnih misli ali poskusa samomora.
The marketing authorisation was renewed on 9 March 2005. 
Dovoljenje za promet je bilo podaljšano 9. marca 2005.
The main measure of effectiveness was response rates. 
Glavno merilo učinkovitosti je bila stopnja odziva.
These contain from 1 to 50 million IU (international units) per millilitre. 
Te oblike vsebujejo od 1 do 50 milijonov mednarodnih enot na mililiter.
The most common side effects with Viraferon in adults (seen in more than 1 patient in 10) are leucopenia (low white blood cell counts), anorexia (loss of appetite), depression, insomnia (difficulty sleeping), anxiety, agitation, nervousness, dizziness, headache, impaired concentration, dry mouth, blurred vision, nausea (feeling sick) or vomiting, abdominal (tummy) pain, diarrhoea, stomatitis (inflammation of the lining of the mouth), dyspepsia (indigestion), alopecia (hair loss), increased sweating, myalgia (muscle pain), arthralgia (joint pain), musculoskeletal pain (pain in the muscles and bones), inflammation at the site of the injection, fatigue (tiredness), rigors (shaking chills), fever, flulike symptoms, asthenia (weakness), irritability, chest pain, malaise (feeling unwell) and weight loss. 
Najpogostejši neželeni učinki zdravila Viraferon pri odraslih (opaženi pri več kot 1 bolniku od 10) so levkopenija (majhno število belih krvnih celic), anoreksija (izguba teka), depresija, nespečnost (težave s spanjem), anksioznost, vznemirjenost, živčnost, omotica, glavobol, motnje koncentracije, suha usta, zamegljen vid, navzeja (občutek slabosti) ali bruhanje, bolečine v trebuhu, driska, stomatitis (vnetje ustne sluznice), dispepsija (slaba prebava), alopecija (izpadanje las), prekomerno potenje, mialgija (bolečine v mišicah), artralgija (bolečine v sklepih), mišičnoskeletne bolečine (bolečine v mišicah in kosteh), vnetje na mestu injiciranja, utrujenost, mrzlica (drgetanje), povišana telesna temperatura, gripi podobni simptomi, astenija (šibkost), razdražljivost, bolečine v prsih, oslabelost (slabo počutje) in izguba telesne mase.
Viraferon is given three times per week (every other day) by subcutaneous injection (under the skin). 
Zdravilo Viraferon se daje trikrat tedensko (vsak drugi dan) s subkutano injekcijo (pod kožo).
Interferons are natural substances produced by the body to help it fight against attacks such as infections caused by viruses. 
Interferoni so naravne snovi, ki jih proizvaja telo za obrambo proti napadi, kot so okužbe, ki jih povzročajo virusi.
The dose and duration of treatment depend on the disease being treated and the response of the patient, with doses ranging from 3 to 10 million IU per square metre of body surface area. 
Odmerek in trajanje zdravljenja sta odvisna od zdravljene bolezni in odziva bolnika, pri čemer se odmerki gibljejo v razponu od 3 do 10 milijonov mednarodnih enot na kvadratni meter telesne površine.
Viraferon has to be stored in a refrigerator (2°C-8°C). 
Zdravilo Viraferon je treba hraniti v hladilniku (2 °C-8 ºC).
The exact way alpha interferons work in viral diseases is not fully understood, but it is thought that they act as immunomodulators (substances that modify how the immune system, the body's defence system, works). 
Natančen način delovanja interferonov alfa pri virusnih boleznih ni v celoti znan, vendar se domneva, da delujejo kot imunomodulatorji (snovi, ki spreminjajo način delovanja imunskega sistema, obrambnega sistema telesa).
The European Commission granted a marketing authorisation valid throughout the EU for Viraferon to SP Europe on 9 March 2000. 
Evropska komisija je dovoljenje za promet z zdravilom Viraferon, veljavno po vsej Evropski uniji, odobrila družbi SP Europe dne 9. marca 2000.
Because Viraferon can be associated with side effects such as depression, patients must be closely monitored during treatment. 
Ker je mogoče zdravilo Viraferon povezati z neželenimi učinki, kot je depresija, je treba bolnike med zdravljenjem pozorno spremljati.
Alpha interferons may also block the multiplication of viruses. 
Interferoni alfa utegnejo tudi blokirati razmnoževanje virusov.
• children and adolescents with a history of severe mental illness, particularly severe depression, 
• otrocih in mladostnikih z anamnezo hude duševne bolezni, še posebej hude depresije,
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) VIRAFERON EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) VIRAFERON Povzetek EPAR za javnost
In children it is used with ribavirin. 
Pri otrocih se uporablja v kombinaciji z ribavirinom.
Treatment with Viraferon should be initiated by a doctor who has experience in the management of the disease it is being used for. 
Zdravljenje z zdravilom Viraferon mora uvesti zdravnik, ki ima izkušnje z zdravljenjem bolezni, za katero se uporablja.
Viraferon should not be used in: 
Zdravila Viraferon se ne sme uporabljati pri:
It is available as a powder and solvent to be made up into a solution for injection or infusion, as a ready-to-use solution for injection and as a multidose pen for injection. 
Na voljo je kot prašek in vehikel za pripravo raztopine za injiciranje ali infundiranje, kot predhodno pripravljena raztopina za injiciranje ter kot večodmerni peresnik za injiciranje.
Other information about Viraferon: 
Druge informacije o zdravilu Viraferon:
Because interferon alfa-2b has been used to treat a number of diseases in the European Union (EU) before, the company that makes Viraferon supplied data from the scientific literature and from studies of its use in children with chronic hepatitis B. The company also supplied information from a number of studies of Viraferon used alone or with ribavirin for the treatment of chronic hepatitis C. These included a total of 2,552 treatment-naïve patients (who had not been treated before) and a total of 345 patients whose disease had relapsed (returned) after previous treatment with interferon. 
Ker se je interferon alfa-2b že prej uporabljal za zdravljenje številnih bolezni v Evropski uniji (EU), je podjetje, ki izdeluje zdravilo Viraferon, predložilo podatke iz znanstvene literature in študij o njegovi uporabi pri otrocih s kroničnim hepatitisom B. Podjetje je predložilo tudi podatke iz številnih študij zdravila Viraferon, uporabljenega samostojno ali v kombinaciji z ribavirinom pri zdravljenju kroničnega hepatitisa C. V teh študijah je sodelovalo skupno 2552 predhodno nezdravljenih bolnikov (ki dotlej še niso prejemali zdravil) in skupno 345 bolnikov, pri katerih se je bolezen ponovila po predhodnem zdravljenju z interferonom.
• patients with thyroid disease unless it is controlled, 
• bolnikih z boleznijo ščitnice, razen če je obvladana,
• patients with epilepsy or other central nervous system problems, 
• bolnikih z epilepsijo ali drugimi motnjami delovanja centralnega živčnega sistema,
The studies showed that Viraferon is effective in the diseases for which it can be used. 
Študije so pokazale, da je zdravilo Viraferon učinkovito pri zdravljenju bolezni, za katere je namenjeno.
It was also effective in children when used with ribavirin, with 46% of the children having responded to treatment at the six-month follow up visit following a year's treatment. 
V kombinaciji z ribavirinom je bilo učinkovito tudi pri otrocih, saj je bilo ob pregledu po šestmesečnem obdobju spremljanja, ki je sledilo enoletnemu zdravljenju, ugotovljeno, da se je na zdravljenje odzvalo 46 % otrok.
• patients with severe kidney or liver disease including that caused by cancer, 
• bolnikih s hudo boleznijo ledvic ali jeter, vključno s takšno, ki jo povzroča rak,
The use of Viraferon in combination with ribavirin has also been studied in 118 hepatitis C treatment-naïve children aged between three and 16 years. 
Uporabo zdravila Viraferon v kombinaciji z ribavirinom so preučevali tudi pri 118 predhodno nezdravljenih otrocih s hepatitisom C, starimi med tri in 16 let.
Viraferon can be used on its own but is best used in combination with ribavirin (an antiviral medicine). 
Pri odraslih je zdravilo Viraferon mogoče uporabljati samostojno, vendar je bolje, če se uporablja v kombinaciji z ribavirinom (protivirusnim zdravilom).
The interferon alfa-2b in Viraferon is produced by a method known as ‘recombinant DNA technology': the interferon alfa-2b is made by a bacterium that has received a gene (DNA), which makes it able to produce it. 
Interferon alfa-2b, ki ga vsebuje zdravilo Viraferon, se proizvaja po metodi, imenovani „rekombinantna DNA tehnologija“: proizvaja ga bakterija, ki je prejela gen (DNA), kar ji omogoča njegovo tvorjenje.
For more information, see the Package Leaflet. 
Za več informacij glejte Navodilo za uporabo.
• hepatitis patients who have liver cirrhosis (scarring) that is causing symptoms or who have recently received medicines that affect the immune system, 
• bolnikih s hepatitisom, ki imajo cirozo jeter, ki povzroča simptome, ali ki so nedavno prejemali zdravila, ki vplivajo na imunski sistem,
What is the risk associated with Viraferon? 
Kakšna tveganja so povezana z zdravilom Viraferon?
What benefit has Viraferon shown during the studies? 
Kakšne koristi je zdravilo Viraferon izkazalo med raziskavami?
The replacement interferon alfa-2b acts in same way as naturally produced interferon alpha. 
Nadomestni interferon alfa-2b deluje na enak način kot naravno proizvedeni interferon alfa.
• chronic hepatitis C (a disease of the liver due to an infection by the hepatitis C virus). 
• kroničnega hepatitisa C (bolezni jeter, ki je posledica okužbe z virusom hepatitisa C).
Similar side effects have been seen in children receiving Viraferon, as well as inhibition of growth. 
Podobni neželeni učinki so bili opaženi pri otrocih, ki so prejemali zdravilo Viraferon, kakor tudi zavirana rast.
Viraferon should not be used in people who may be hypersensitive (allergic) to interferon alfa-2b or any of the other ingredients. 
Zdravilo Viraferon se ne sme uporabljati pri ljudeh, ki utegnejo biti preobčutljivi za (alergični na) interferon alfa-2b ali katero koli drugo sestavino.
• patients with a history of certain disorders of the immune system, or who have had an organ transplant and are taking medicines that suppress the immune system, 
• bolnikih, ki imajo določene motnje imunskega sistema v anamnezi ali so imeli presaditev organa in jemljejo zdravilo za zaviranje delovanja imunskega sistema,
Viraferon is used for the treatment of: 
Zdravilo Viraferon se uporablja za zdravljenje:
• patients with a history of severe heart disease, 
• bolnikih z anamnezo hudega obolenja srca,
Viraferon is a medicine containing the active substance interferon alfa-2b. 
Viraferon je zdravilo, ki vsebuje zdravilno učinkovino interferon alfa-2b.
For the full list of all side effects reported with Viraferon, see the Package Leaflet. 
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Viraferon, glejte Navodilo za uporabo.
Viraferon was also shown to have a benefit in children with chronic hepatitis B. Viraferon, with or without ribavirin, was shown to be effective in treating hepatitis C in both treatment-naïve and relapsed adults. 
Zdravilo Viraferon je izkazalo koristi tudi pri otrocih s kroničnim hepatitisom B. Zdravilo Viraferon v kombinaciji z ribavirinom ali brez njega je bilo učinkovito pri zdravljenju hepatitisa C pri predhodno nezdravljenih odraslih in odraslih s ponovitvijo bolezni.
• chronic (long-term) hepatitis B (a disease of the liver due to an infection by the hepatitis B virus) 
• kroničnega (dolgotrajnega) hepatitisa B (bolezni jeter, ki je posledica okužbe z virusom hepatitisa B) pri odraslih;
The Committee for Medicinal Products for Human Use (CHMP) decided that Viraferon's benefits are greater than its risks for the treatment of chronic hepatitis B and C. The Committee recommended that Viraferon be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Viraferon pri zdravljenju kroničnega hepatitisa B in C večje od z njim povezanih tveganj.
The full EPAR for Viraferon is available here. 
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Viraferon je na voljo tukaj.
Why has Viraferon been approved? 
Zakaj je bilo zdravilo Viraferon odobreno?
The active substance in Viraferon, interferon alfa-2b, belongs to the group ‘interferons'. 
Zdravilna učinkovina zdravila Viraferon, interferon alfa-2b, spada v skupino interferonov.
For a list of all restrictions with Viraferon, see the Package Leaflet. 
Za celoten seznam omejitev za zdravilo Viraferon glejte Navodilo za uporabo.
How has Viraferon been studied? 
Kako je bilo zdravilo Viraferon raziskano?
What is Viraferon used for? 
Za kaj se zdravilo Viraferon uporablja?
What is Viraferon? 
Kaj je zdravilo Viraferon?
How is Viraferon used? 
Kako se zdravilo Viraferon uporablja?
How does Viraferon work? 
Kako zdravilo Viraferon deluje?
• Not drink Grapefruit Juice 
• ne sme piti soka grenivke;
The PAC must include the following key messages: 
Kartica OKB mora vsebovati naslednja ključna sporočila:
• Have ever had an abnormal electrocardiogram (ECG) 
• je kadar koli imel nenormalen elektrokardiogram (EKG);
• Is taking allergy medicines 
• jemlje zdravila proti alergiji.
• Is taking medications to treat epilepsy, bacterial or fungal infections, HIV infection, depression or heart rhythm disorders 
• jemlje zdravila proti epilepsiji, bakterijskim ali glivičnim okužbam, okužbi z virusom HIV, depresiji ali motnjam srčnega ritma;
• A dose reduction of Ranexa may be needed in combination with: 
• Zmanjšanje odmerka zdravila Ranexa bo morda potrebno v kombinaciji z:
• Call their doctor if they feel dizzy or sick, become sick or experience any unexpected symptoms after starting Ranexa. 
• mora poklicati zdravnika, če je omotičen ali če mu je slabo, če bruha ali če ima kakršne koli nepričakovane simptome po začetku jemanja zdravila Ranexa.
• That the card should be shown to any doctor involved in their treatment 
• Bolnik mora kartico pokazati vsakemu zdravniku, ki sodeluje v njegovem zdravljenju.
• Inform the patient about the potential for an interaction with other prescribed medicinal products and to contact his/her doctor in case of dizziness, nausea or vomiting. 
• Bolnika je treba obvestiti o možnosti interakcij z drugimi predpisanimi zdravili in mu naročiti, naj obvesti svojega zdravnika, če se pojavijo omotica, navzeja ali bruhanje.
• With certain other risk factors listed in the product information 
• z nekaterimi drugimi dejavniki tveganja, navedenimi v informacijah o zdravilu.
• Taking certain other drugs mentioned in the product information 
• ki jemljejo nekatera druga zdravila, omenjena v informacijah o zdravilu;
• Ranexa is contraindicated in patients taking: 
• Zdravilo Ranexa je kontraindicirano pri bolnikih, ki jemljejo:
• Caution should be exercised when prescribing Ranexa to patients: 
• Previdnost je potrebna pri predpisovanju zdravila Ranexa bolnikom:
• Liver problems 
• ima težave z jetri;
ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
DODATEK IV POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO IZVAJATI DRŽAVE ČLANICE
Patient information The PAC should include the following information for the patient: 
Informacije za bolnika Kartica OKB mora vsebovati naslednje informacije za bolnika:
The Pharmacist should be requested to distribute a PAC to each patient at the time Ranexa is dispensed. 
Od farmacevta je treba zahtevati, da kartico OKB da vsakemu bolniku, kadar izda zdravilo Ranexa.
• Class Ia (e.g. quinidine) or Class III (e.g. dofetilide, sotalol) antiarrhythmics other than Amiodarone 
• antiaritmike razreda Ia (npr. kinidin) ali razreda III (npr. dofetilid, sotalol), razen amiodarona.
• Potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazol, posaconazol, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone) 
• močne zaviralce CYP3A4 (npr. itrakonazol, ketokonazol, vorikonazol, posakonazol, zaviralce proteaze virusa HIV, klaritromicin, telitromicin, nefazodon);
Health Care Professional information The PAC should include the following information for the healthcare professional information regarding Ranexa: 
Informacije za zdravnike Kartica OKB mora vsebovati naslednje informacije za zdravnike o zdravilu Ranexa:
• Moderate CYP3A4 inhibitors (e.g. diltiazem, erythromycin, fluconazole) 
• zmernimi zaviralci CYP3A4 (npr. diltiazemom, eritromicinom, flukonazolom);
• To refer to the Ranexa SPC prior to prescribing any medications to the patient, as there are potential drug interactions which should be taken into consideration. 
• Navodilo, naj pred predpisovanjem katerega koli zdravila bolniku preberejo povzetek glavnih značilnosti zdravila, saj obstajajo morebitne interakcije z drugimi zdravili, ki jih je treba upoštevati.
• That prior to Ranexa treatment the patient should tell their doctor if they have any of the following: 
• Pred zdravljenjem z zdravilom Ranexa mora bolnik obvestiti zdravnika, če:
The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented: The Member States shall agree the details of a Patient Alert Card (PAC) with the MAH, who must provide this PAC directly to the pharmacy with each Ranexa shipment. 
Država članica se mora o podrobnostih na Opozorilni kartici za bolnika (OKB) dogovoriti z imetnikom dovoljenja za promet z zdravilom, ki mora kartico OKB poslati neposredno lekarnam ob vsaki pošiljki zdravila Ranexa.
• P-gp inhibitors (e.g. ciclosporin, verapamil) 
• zaviralci P-gp (npr. ciklosporinom, verapamilom)
• Kidney problems 
• ima težave z ledvicami;
• That during treatment with Ranexa the patient should: 
• Med zdravljenjem z zdravilom Ranexa bolnik:
• To ensure to take a list of all their other medicines with them at any visit to the health care professional. 
• Ob vsakem obisku zdravnika mora bolnik s sabo vzeti seznam vseh drugih zdravil, ki jih jemlje.
• To refer to the Ranexa package leaflet for more information. 
• Bolnik lahko več informacij najde v navodilu za uporabo zdravila Ranexa.
• Is taking the herbal remedy St John's Wort 
• jemlje zeliščni pripravek, ki vsebuje šentjanževko;
50 ml (16 mg/ml) 1 vial 
50 ml (16 mg/ml) 1 viala
800 mg Concentrate for solution for infusion 
800 mg Koncentrat za raztopino za infundiranje
Intravenous use Vial (glass) 
Viala (steklena)
The capsules must never be swallowed. 
Kapsule se ne smejo nikoli pogoltniti.
The evening dose should be taken two to three hours before bedtime. 
Večerni odmerek se vzame dve do tri ure pred spanjem.
The European Commission granted a marketing authorisation valid throughout the European Union for Bronchitol on 13 April 2012. 
Evropska komisija je dovoljenje za promet z zdravilom Bronchitol, veljavno po vsej Evropski uniji, odobrila dne 13. aprila 2012.
This means that it can promote osmosis (the flow of liquid across a membrane). 
To pomeni, da lahko spodbuja osmozo (pretok tekočine skozi membrano).
This is a summary of the European public assessment report (EPAR) for Bronchitol. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Bronchitol.
Some patients also received additional treatment with rhDNase (another treatment for cystic fibrosis). 
Nekateri bolniki so prejeli tudi dodatno zdravljenje z rhDNAzo (drugo zdravilo za cistično fibrozo).
FEV1 is the maximum volume of air a person can breathe out in one second. 
FEV1 je največji volumen zraka, ki ga bolnik lahko izdihne v eni sekundi.
In order to obtain further information on effectiveness and safety of Bronchitol in children and adolescents with cystic fibrosis the CHMP requested the company to carry out a study in this patient group. 
Za pridobitev dodatnih informacij o učinkovitosti in varnosti uporabe zdravila Bronchitol pri otrocih in mladostnikih s cistično fibrozo je odbor CHMP zahteval, da družba opravi študijo s to skupino bolnikov.
Other information about Bronchitol 
Druge informacije o zdravilu Bronchitol
For more information about treatment with Bronchitol, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Bronchitol preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The effects of Bronchitol were first tested in experimental models before being studied in humans. 
Učinki zdravila Bronchitol so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The recommended dose is 400 mg (which requires the inhalation of the content of 10 capsules loaded individually into the inhaler) twice a day in the morning and in the evening. 
Priporočeni odmerek je 400 mg (kar pomeni vdihavanje vsebine 10 kapsul; vsebino vsake kapsule posebej je treba prenesti v inhalator) dvakrat dnevno, zjutraj in zvečer.